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Abstract
The great challenges for researchers working in the field of vaccinology are optimizing DNA
vaccines for use in humans or large animals and creating effective single-dose vaccines using
appropriated controlled delivery systems. Plasmid DNA encoding the heat-shock protein 65
(hsp65) (DNAhsp65) has been shown to induce protective and therapeutic immune responses in
a murine model of tuberculosis (TB). Despite the success of naked DNAhsp65-based vaccine to
protect mice against TB, it requires multiple doses of high amounts of DNA for effective
immunization. In order to optimize this DNA vaccine and simplify the vaccination schedule, we
coencapsulated DNAhsp65 and the adjuvant trehalose dimycolate (TDM) into biodegradable poly
(DL-lactide-co-glycolide) (PLGA) microspheres for a single dose administration. Moreover, a
single-shot prime-boost vaccine formulation based on a mixture of two different PLGA
microspheres, presenting faster and slower release of, respectively, DNAhsp65 and the
recombinant hsp65 protein was also developed. These formulations were tested in mice as well as
in guinea pigs by comparison with the efficacy and toxicity induced by the naked DNA preparation
or BCG. The single-shot prime-boost formulation clearly presented good efficacy and diminished
lung pathology in both mice and guinea pigs.
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Background
Tuberculosis (TB) still remains a major health problem
affecting millions of people worldwide [1]. The only TB
vaccine currently available is Mycobacterium bovis BCG.
However, the efficacy of BCG still remains controversial,
especially against pulmonary TB in young adults, and
development of a better vaccine is urgently required to
counteract the global threat of TB [2-4]. Over the past 20
years, the technology of vaccine development has
changed radically. The strategy of using the pathogen itself
has given way to creating alternate forms of antigens (such
as genes encoding specific antigens), new adjuvants and
new delivery systems, as well as employing the recently
devised prime-boost concept [5-8]. Thus, several strategies
have been employed for generation and evaluation of new
TB vaccines. Recombinant BCG strains, DNA-based vac-
cines, live attenuated M. tuberculosis vaccines and subunit
vaccines formulated with novel adjuvants have shown
promise in preclinical animal challenge models. The abil-
ity of DNA vaccines to elicit Th1 biased CD4+ responses
and strong CTL responses make them particularly attrac-
tive weapon against M. tuberculosis infection [9,10].
Experimental data collected over several years by our
group showed that the DNA vaccine codifying the 65 kDa
heat shock protein from M. leprae (DNAhsp65) presented
a prophylactic and therapeutic effect in a murine model of
TB [11-13]. Although the prophylactic effect demon-
strated initially with this vaccine was equal from live BCG
vaccine in mice and the feature of this protection were
associated with the presence of CD8+/CD44hi IFN-γ-pro-
ducing/cytotoxic cells [14] there was a necessity to opti-
mize the vaccine formulation in order to improve efficacy
and diminish possible toxicity. The literature on plasmid
DNA in vaccination suggests that four doses of naked
DNA injected intramuscularly might not be sufficient for
the generation of protective humoral and cellular
immune responses against infectious diseases in large ani-
mals [15-18]. One of the pharmaceutical measures to
improve DNA vaccines has been to ameliorate the uptake
of DNA into professional antigen-presenting cells by
using DNA entrapped into polymeric particles. Biode-
gradable poly (lactic-co-glycolic acid) microspheres
(PLGA) represent an attractive candidate for vaccine deliv-
ery [19]. Therefore, as an alternative strategy to confer
long-lasting protection against TB in mice and guinea
pigs, we evaluated the encapsulation of the hsp65-DNA
and rhsp65 into biodegradable PLGA microspheres that
have the potential to release the antigen in a sustained
fashion. Due to its ability to induce the secretion of
cytokines in a Th1 pattern of immune response [11], tre-
halose dimycolate (TDM), a glycolipid from the Mycobac-
terium cell wall, was included in the formulations as an
adjuvant. Moreover, a more recently devised tool for gen-
erating a protective and long-lasting immune response
involves combining different vehicles carrying the same
immunogen in heterologous prime-boost protocols [20].
These prime-boost vaccination strategies consist of using
two different vaccines, each encoding the same antigen,
administered some weeks apart. In the prevention of TB,
the prime-boost strategy of combining DNA priming and
boosting with BCG or recombinant proteins has been
evaluated by various authors [21,22]. Such protocols typ-
ically require more than one high amount of DNA dose
for priming, followed by a booster with live vectors,
thereby necessitating the use of large quantities of DNA.
Taking into account these factors we also evaluated both
in mice and guinea pigs the use of a new concept in vac-
cine formulation based on a mixture of two different
PLGA microspheres, presenting faster and slower release
of, respectively, DNA encoding hsp65 and the recom-
binant hsp65 protein [20]. Our aim was to achieve DNA
priming and protein boosting after a single-dose vaccina-
tion.
Materials and methods
Animals
Outbred Female Hartley guinea pigs weighing 300–350 g
and young adult BALB/c mice were obtained from the ani-
mal facilities of the campus of Ribeirão Preto, Universi-
dade de São Paulo, and were maintained under standard
laboratory conditions. Infected animals were kept in bio-
hazard facilities, housed in cages within a laminar flow
safety enclosure. All experiments were approved and con-
ducted in accordance with guidelines of the Animal Care
Committee of the University.
Plasmid derivation
The construction of a pVAX plasmid (Invitrogen) contain-
ing the cytomegalovirus (CMV) promoter and a cDNA
encoding the HSP65 gene for M. leprae (pVAX-HSP65) has
been previously described [23]. The vector without the
hsp65 gene was used as control. DH5α Escherichia coli
transformed with plasmid pVAX or the plasmid contain-
ing the hsp65 gene (DNAhsp65) was cultured in LB liquid
medium (Gibco-BRL) containing kanamycin (100 μg/
mL). Plasmid DNA was obtained as described in the End-
oFree plasmid purification handbook (Qiagen, Ltd.,
Crawley, UK). Spectrophotometric analysis using Gene
Quant II apparatus (Pharmacia Biotech, Buckingham-
shire, UK) revealed the 260/280 nm ratios to be ≥ 1.80.
The purity of DNA preparations was confirmed on the 1%
agarose gel.
Recombinant hsp65 protein
E. coli BL21 transformed with the plasmid containing the
mycobacterial hsp65 gene was cultured in LB medium
containing ampicillin (100 μg/μl). The bacterial growing
was monitored by spectrophotometry in a Shimadzu UV-
1650 spectrophotometer. When the OD reached the value
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of 0.6, the culture was induced with 0.1 M of IPTG (Gibco,
BRL, Gaithersburg, MD, USA) and incubated at 30°C
under agitation for 4 h. Protein purification was done as
previously described [24].
Microspheres preparation
Microspheres were obtained by the double emulsion/sol-
vent evaporation technique as previously described [25].
Briefly, 30 ml dichloromethane solution containing 400
mg of polymer PLGA 50:50 or PLGA 75:25 (Resomerfrom
Boehringer Ingelheim, Ingelheim, Germany) and 0.5 mg
of TDM (Sigma, St Louis, USA) was emulsified with 0.3 ml
of an inner aqueous phase containing 5 mg of DNA
(DNAhsp65 or DNAv) or 1 mg of recombinant hsp65
protein using a T25 Ultraturrax homogenizer (IKA –
Labortechnik, Germany) to produce a primary water-in-
oil emulsion. This emulsion was then mixed with 100 ml
of an external aqueous phase containing 1–3 % poly vinyl
alcohol (Mowiol 40–88, Aldrich Chemicals, Wankee, WI,
USA) as surfactant, to form a stable water-in-oil in-water
emulsion. The mixture was stirred for 6 h with a RW20
IKA homogenizer for solvent evaporation. Microspheres
were collected and washed three times with sterile water,
freeze-dried and stored at 4°C.
Particle diameter analysis, rate of DNA and protein 
encapsulation, endotoxin levels, and kinetics of DNA and 
protein release
Particle diameter distribution was evaluated by laser dif-
fractometry in a Shimadzu Sald 2164 apparatus (Shi-
madzu, Japan). Results are expressed as median value of
diameter distribution. Plasmid encapsulation rate was
determined adapted from Barman et al. [26]. Briefly, 10
mg of microspheres were ressuspended in 0.2 ml of TE
buffer and 500 μl of chloroform were added to the sus-
pension. The mixture was maintained under agitation for
60 min. The sample was centrifuged at 14,000 rpm for 5
min and the supernatant was separated for analysis. The
amount of DNA was determined as described before using
the Gene Quant II. The protein encapsulation rate was
determined after addition of 0.2 ml of acetonitrile. The
sample was incubated in an ultrasound bath for 15 min
allowing the complete solubilization of microspheres and
it was followed by addition of water (1:1). The protein
content was assayed by using the Comassie reagent
(Pierce, Rockford, IL, USA). The protein concentration
was determined at 600 nm using an ELISA reader (960,
Metertech). The kinectics of protein release from micro-
spheres was evaluated by ressuspending 30 mg of protein-
loaded microspheres in 3 ml of PBS containing sodium
azide (0.05% w/v). The suspension was maintained at
37°C under constant agitation at 200 rpm. In pre-estab-
lished time intervals, samples of the supernatant (0.1 ml)
were collected and replaced with fresh buffer. The protein
concentration in the supernatant was determined by using
the Comassie Reagent as previously described [19]. The
endotoxin detection in formulations was made by Limulus
Amebocyte Lysate test (LAL test, QCL-1000, Bio Whit-
taker, CAMBREX). For this purpose microspheres were
ressuspended in PBS and the suspension was maintained
in vortex until the complete homogenization.
Immunization procedures
Immunization either in mice or guinea pigs was by one of
the following treatments, and five to ten animals were
used in each group. For naked DNA vaccination, the plas-
mid DNAhsp65 was administered by intramuscular injec-
tion of 100 μg DNA in saline into each quadriceps muscle
on three occasions at 2-week intervals (total dose of 300
μg of plasmid). Additional control animals received saline
or control vector (DNAv) by using the same amount and
schedule of treatments. BCG (Pasteur strain) was given as
a single subcutaneous injection of about 105 live bacteria
in 50 μl saline. Animals received a single-dose of an intra-
muscular injection of 2.5 mg of microspheres in 50 μl
saline into each quadriceps muscle. Two microspheres
formulations were evaluated: DNAhsp65/TDM-loaded
PLGA 50:50 microspheres (Me-DNAhsp65/TDM) and a
mixture (1:1 w/w) of DNAhsp65/TDM-loaded PLGA
50:50 microspheres and recombinant hsp65 protein/
TDM-loaded PLGA 75:25 microspheres (Me-Prime/
boost). Additional control animals received DNAvector/
TDM-loaded PLGA 50:50 microspheres (Me-control).
Challenge infection of immunized animals
Guinea pigs and mice were challenged by intratracheal
route with 105 colony-forming units (CFU) of M. tubercu-
losis H37Rv, 30 days after the last immunization. Animals
were killed 30 days after infection and the number of live
bacteria in the lungs was determined as CFU by plating
10-fold serial dilutions of homogenized tissue on Middle-
brook 7H11 agar (Difco), counting colonies after 21 days
and results expressed as log10 CFU/g lung tissue.
Histology
The upper left lobe of each animal was fixed in 10% for-
malin, embedded in paraffin blocks, prepared routinely,
then sectioned for light microscopy. Sections (5 μm each)
were stained either with haematoxylin & eosin method.
Cellular infiltrate in lung parenquima was analysed by
morphometrical measures. Results were expressed as per-
cent of cellular infiltrate in lung parenchyma of animals
previously vaccinated with different formulations and
challenged with M. tuberculosis.
Statistical analysis
Results were expressed as mean (±) SD. Significance of dif-
ference among groups was calculated by Student's t tests.
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Results
Encapsulation efficiency and physical characteristics of 
DNAhsp65/TDM-loaded microspheres
Plasmid DNA was incorporated into PLGA microspheres
by the double emulsion/solvent evaporation method.
Encapsulation efficiency varied from 30 to 50% for DNA
and around 70% for protein. Table 1 shows the amount
of entrapped DNA and protein in the different formula-
tions. In this work, particles were designed to have diam-
eter smaller than 10 μm. Particles encapsulating DNA
were greater in diameter than microspheres encapsulating
protein (Table 1). The association of TDM with protein or
DNA in microspheres did not change the diameter or
loading rate after encapsulation. Microspheres population
presents characteristic Gaussian distribution of diameter.
The microspheres formulations were also assayed for
detection of endotoxin activity using the Limulus amebo-
cyte assay (LAL test). We showed in the Table 1 that endo-
toxin activity in all microsphere formulations was lower
than 0.4 EU/mg. According to the European Pharmaco-
poeia the safety level for endovenous administration is 5
EU/Kg/hour that corresponds to 0.1 EU per mouse (20 g)
per hour.
In vitro hsp65 protein, TDM and DNA release profiles from 
PLGA microspheres
The in vitro release profiles of recombinant hsp65 protein
entrapped into PLGA microspheres were evaluated in vitro
for over 120 days. The results showed that microspheres
released all the encapsulated protein in a 90-day interval.
Most of the protein was released after 50 days (Figure 1).
The Me-DNAhsp65/TDM formulation released around
80% of their DNA or TDM (not shown) load after 20 days.
Protection against M. tuberculosis replication in lungs of 
vaccinated animals
As shown in Table 2, a single dose of Me-DNAhsp65/TDM
formulation was able to protect mice as well as guinea
pigs against M. tuberculosis as efficiently as three doses of
naked DNAhsp65. There was a significant reduction in the
number of bacterial burden compared to control mice,
which is similar to the reduction provided by BCG in both
animal models, which therefore can be considered as
good protection. The same level of protection as described
for Me-DNAhsp65/TDM was observed in mice and guinea
pigs vaccinated with Me-Prime/boost formulation in a
single dose.
Histological analysis of lungs from mice and guinea pigs 
vaccinated and challenged with virulent strain of M. 
tuberculosis
Thirty days after challenge, animals were sacrificed and
lungs were processed for histological analysis. Non-vacci-
nated and challenged animals were used as control groups
and the results are illustrated in Table 3. We observed that
in the mice control group (no vaccinated and M. tubercu-
losis-infected) around 70% of lung parenchyma was com-
promised with granuloma formation widely distributed,
presenting cellular infiltrate containing mainly lym-
phocytes, with few macrophages and without neutrophils.
Mice or guinea pigs injected with DNAhsp65 (naked
DNA) presented a very low and similar compromising of
lungs. However, there were few and small granulomas in
this group with cell infiltrate composed by lymphocyte,
macrophages, neutrophils and plasmocytes without of
necrotic areas. The group vaccinated with Me-DNAhsp65/
TDM formulation presented lower lung compromising
with lymphocytes and macrophage infiltration, as well as
few neutrophilic infiltrations (Table 3). Me-Prime/boost
vaccinated mice also presented lower lung compromising
with cellular infiltration characterized by high amount of
macrophages. In some areas tissue showed lymphocytes
concentrated around bronchus.
Discussion
The high incidence of TB around the world and the inabil-
ity of BCG to protect certain populations clearly indicate
that an improved vaccine against TB is needed. Currently,
many vaccines are under development and there is a
desire to simplify vaccination schedules by decreasing the
number of doses. With this purpose, various substances
have been added to vaccines and certain formulations
Table 1: Median values of diameter distribution, encapsulation rate, and endotoxin levels in each formulation
Formulation Composition Average diameter
(μm)
Encapsulation rate
(μg/mg of microspheres)
DNA – Protein
Endotoxin level
(UE/mg)
Me-Control - 100% of DNAv plus TDM-loaded PLGA 50:50 
microspheres
4.0 4.11 - 0.011
Me-DNAhsp65/TDM - 100% of DNAhsp65 plus TDM-loaded PLGA 
50:50 microspheres
3.7 4.97 - 0.028
Me-Prime/boost A mixture of PLGA microspheres containing:
- 50% of DNAhsp65 plus TDM-loaded PLGA 
50:50 microspheres
3.5 4.90 - 0.030
- 50% rHsp65 protein plus TDM-loaded PLGA 
75:25 microspheres
2.4 - 1.70 0.053
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have been devised in an attempt to render vaccines more
effective [27]. Despite of success of naked DNAhsp65-
based vaccine to protect mice against TB, it requires mul-
tiple doses of high amount of plasmid for effective immu-
nization, which could lead to an exacerbated
inflammatory reaction in the lungs of challenged mice or
guinea pigs. To optimize this DNA vaccine, we used an
approach where adjuvants with targeting and immunos-
timulatory properties prepared by microencapsulation
techniques are administered in conjunction with the
DNA-encoding antigen. BALB/c mice immunized with a
single dose of Me-DNAhsp65/TDM-loaded microspheres
produced high levels of IgG2a subtype antibody and high
amounts of IFN-γ in mice as previously described [20,24].
Here we show that Me-DNAhsp65/TDM-loaded micro-
spheres were also able to confer protection as effective as
that attained after three doses of naked DNA administra-
tion either in mice or guinea pigs. This new formulation
also allowed a ten-fold reduction in the DNA dose when
compared to naked DNA as well as a significant reduction
in the cellular infiltrate in the lung parenchyma of mice
and guinea pigs. Thus, this combination of DNA vaccine
and adjuvants with immunomodulatory and carrier prop-
erties holds the potential for an improved vaccine against
TB. PLGA biodegradable microspheres also have the
potential to act as mediators of DNA transfection targeted
to phagocytic cells such as macrophages or dendritic cells,
and to protect against biological degradation by nucleases
[28,29]. We previously show that DNAhsp65-loaded
microsphere without adjuvant was unable to protect mice
against challenge [23]. Thus, the entrapment of DNA plus
an immunostimulant compound into PLGA micro-
spheres could be an interesting strategy for vaccine formu-
lation. The adjuvant effect of purified TDM on immune
response has been recognized long ago [30]. The immu-
nostimulatory activities made TDM an attractive candi-
date for adjuvant use in vaccine formulation. Moreover,
the polymer has an established clinical safety record and
its slow degradation permits sustained delivery of antigen
[31]. Hence, if the quality of the immunity is dependent
on antigen persistency, or if compliance is compromised
due to socio-economic or demographic circumstances,
PLGA-like microspheres offer a potential advantage for
the vaccines.
In vitro release profile of DNAhsp65 (▲) and recombinant hsp65 protein (■) encapsulated into PLGA erived micro-sphe esFigure 1
In vitro release profile of DNAhsp65 (▲) and recombinant 
hsp65 protein (■) encapsulated into PLGA derived micro-
spheres. PLGA derived microspheres containing DNA or 
rHsp65 were ressuspended in PBS and maintained at 37°C 
under constant agitation. In pre-established time intervals, 
samples of the supernatant were collected and replaced with 
fresh buffer. The DNA or protein concentration in the 
supernatants were determined and represented as a percent-
age o cumulative release. Results are shown as mean μg ± SD 
from groups of five samples.
Table 2: Bacterial replication in lungs from mice and guinea pigs vaccinated and challenged with M. tuberculosis
Vaccine formulationsa Miceb Guine-pigsb
No vaccination 6.12 ± 0.40 5.43 ± 0.38
BCG 3.25 ± 0.38* 3.80 ± 0.24*
DNAv (naked DNA) 6.02 ± 0.35 5.68 ± 0.29
DNAhsp65 (naked DNA) 4.76 ± 0.26* 4.90 ± 0.25*
Me-DNAhsp65/TDM 4.55 ± 0.28* 4.12 ± 0.25*
Me-Prime/boost 4.21 ± 0.30* 4.54 ± 0.27*
aMice and guinea pigs (5–10 animals per group) were immunized by the following schedule: PBS (three intramuscular injection at 2-week intervals); 
DNA-hsp65 (three intramuscular injection of 100 ug DNA plasmid encoding M. leprae hsp65 gene at 2-week intervals); DNAv (plasmid DNA 
without the hsp65 gene administered at the same scheme for DNAhsp65); BCG (single intradermic injection of about 105 live bacteria in 50 ml 
saline); Me-DNAhsp65/TDM-loaded microspheres (single intramuscular injection of DNAhsp65 plus TDM-loaded PLGA 50:50 microspheres); Me-
Prime/boost (single intramuscular injection of a mixture of PLGA microspheres as described in Table 1). Guinea pigs and mice were challenged by 
intratracheal route with 105 CFU of M. tuberculosis H37Rv, 30 days after the last immunization.
bAnimals were killed 30 days after infection and the number of live bacteria in the lungs was determined as mean number of CFU ± SD (log10 
values)/g lung tissue.
* Indicate that the effects of vaccination were significant compared with data from animals not vaccinated and challenged with M. tuberculosis 
(Student's t-tests, P < 0.05).
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A more recently devised tool for generating a protective
and long-lasting immune response involves combining
different vehicles carrying the same immunogen in heter-
ologous prime-boost protocols [20]. These prime-boost
vaccination strategies consist of using two different vac-
cines, each encoding the same antigen, administered
some weeks apart. Most prime-boost protocols currently
under evaluation include priming with DNA and boosting
with viral vectors [32,33]. This strategy resurrects ques-
tions concerning the safety of using live attenuated viruses
that have been replaced by subunit or DNA vaccines
alone. In the prevention of TB, the prime-boost strategy of
combining DNA priming and boosting with BCG or
recombinant proteins has been evaluated by various
authors [17,19]. Such protocols typically require more
than one DNA dose for priming, followed by a booster
with live vectors, thereby necessitating the use of large
quantities of DNA. As shown above, the encapsulation of
antigen into PLGA microspheres allows the development
of controlled-release delivery systems, in which the release
profile of the encapsulated material can be tailored to spe-
cific purposes. Taking advantage of this fact, we evaluated
the use of a vaccine formulation based on a mixture of two
different PLGA microspheres, presenting faster and slower
release of, respectively, DNA-hsp65 and the rhsp65 (Fig-
ure 1). Our aim was to achieve DNA priming and protein
boosting after a single-dose vaccination. We demon-
strated previously in mice [20], that the Me-Prime/boost
formulation induced high levels of anti-hsp65 antibodies
and IFN-γ, which remained high 90 days after vaccination,
whereas the Me-DNAhsp65/TDM formulation was una-
ble to sustain antibody levels in the same fashion. Here we
show that mice or guinea pigs challenged with a virulent
strain of M. tuberculosis 30 days after vaccination, we
observed significantly lower numbers of CFUs in the
lungs of those vaccinated with Me-Prime/boost formula-
tion than in the lungs of the controls. Moreover, we
showed that the infection remained under control and the
lung parenchyma unaffected only in the group immu-
nized with the Me-Prime/boost formulation. These data
suggest that Me-Prime/boost is a formulation capable of
sustaining the protective response in mice and guinea
pigs. Therefore, using biodegradable microspheres in a
single dose seems to be a promising strategy for stimulat-
ing long-lasting immune responses in large animals.
In this study, we set out to overcome significant obstacles
currently faced in for the field of DNA vaccine develop-
ment. We described, for the first time, the development of
a single dose/prime-boost DNA vaccine formulation for
immunizing mice and guinea pigs against mycobacterial
challenge. This new technology allows radically different
approaches to the problems of immunization with DNA
vaccines. Furthermore, using combinations of vaccines
and alternative routes of administration will allow
researchers to customize vaccination programs. Moreover,
this new technique may increase veterinarian and patient
acceptance of vaccination by reducing the number of
injections and avoiding the use of boosters containing live
vectors. Using this technology, vaccinologists could
develop many DNA vaccines that would induce specific
forms of immunity, access new routes of delivery, provide
increased safety when necessary, be more stable and lower
costs. We believe that this strategy can be applied to vac-
cines for humans and to other veterinary vaccines, thereby
having a tremendous impact on the control of infectious
diseases in humans and in large animals.
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* Indicate that the effects of vaccination were highly significant compared with data from animals not vaccinated and challenged with M. tuberculosis 
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